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ABSTRACT
More than 40 000 hematopoietic cell transplants (HCTs) are performed worldwide each year. With improve-
ments in transplant technology, larger numbers of transplant recipients survive free of the disease for which
they were transplanted. However, there are late complications that can cause substantial morbidity. Many
survivors are no longer under the care of transplant centers, and many community health care providers may
be unfamiliar with health matters relevant to HCT. The Center for International Blood and Marrow Trans-
plant Research (CIBMTR), European Group for Blood and Marrow Transplantation (EBMT), and American
Society for Bone Marrow Transplantation (ASBMT) have developed these recommendations to offer care
providers suggested screening and prevention practices for autologous and allogeneic HCT survivors.
© 2006 European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant
Research, and the American Society for Blood and Marrow Transplantation
KEY WORDS
Late effects ● HCT (hematopoietic cell transplantation) ● Screening ● Prevention
p
w
s
e
g
t
iNTRODUCTION
More than 40 000 hematopoietic cell transplants
HCTs) are performed worldwide each year. With
mprovements in transplant technology, more trans-
his article is being published concurrently in Bone Marrow Transplan-
ation, 2006;37:249-261. The articles are identical except for minor
tylistic and spelling differences in keeping with each journal’s style. Eitherditation can be used when citing this article.
38lant recipients now survive free of the disease for
hich they were transplanted. There are tens of thou-
ands of HCT survivors alive today.
Although HCT is associated with considerable
arly morbidity and mortality, long-term survivors
enerally enjoy good health. This notwithstanding,
here are sequelae that can cause substantial morbid-
ty. Optimizing outcomes through prevention or early
etection of complications and mitigation of disability
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Screening and Preventive Practices for Long-Term Survivors after HCT
Bre high priorities. Many survivors are no longer un-
er the care of transplant centers, and many commu-
ity health care providers may be unfamiliar with
ealth matters relevant to HCT. The purpose of these
ecommendations is to offer care providers suggested
creening and prevention practices for autologous and
llogeneic HCT survivors. Our goal is to provide an
verview of the late complications faced by transplant
ecipients and provide reasonable recommendations
or care. Complications of the immediate post-HCT
eriod are extensively reviewed elsewhere [1-6]. Sim-
larly, because of variability in the anticipated course
f diseases for which transplantation is performed, this
ocument does not include speciﬁc recommendations
egarding disease follow-up. Comprehensive guidelines
or follow-up of pediatric cancer survivors recently
eveloped by the Children’s Oncology Group can be
ound at http://www.survivorshipguidelines.org.
The following recommended screening and preven-
ive practices were developed by a consensus panel
ormed by members of the Center for International
lood and Marrow Transplant Research (CIBMTR),
uropean Group for Blood and Marrow Transplanta-
ion (EBMT), and American Society for Bone Marrow
ransplantation (ASBMT). These recommendations fo-
us on risks faced by patients beyond 6 months following
ransplantation. Summary recommendations can be
ound in Tables 1 and 2. These recommendations are
ot all based on evidence derived from randomized or
ther controlled trials, since in most cases preventive
ractices have not been subjected to such trials. Most
ecommendations derive from studies that have identi-
ed speciﬁc complications in long-term survivors and
he risk factors associated with them. As such, they rep-
esent sensible practices to optimize outcomes. The rec-
mmendations should not be judged as mandatory for all
ecipients; good medical practice and judgment dictate
hat certain recommendations may not be applicable or
ay even be contraindicated in individual patients or
roups of patients.
A broad constellation of medical issues faced by
ate survivors of transplantation is presented. Most of
he late complications discussed here pertain particu-
arly to allogeneic recipients. However, autologous
ecipients are at risk for many of the late complica-
ions and may experience unusual toxicity or immune
mpairment following transplantation that places
hem at risk similar to allogeneic recipients. There-
ore, although some of the following recommenda-
ions do not generally apply to autologous recipients,
roviders should remain alert to these complications
n all patients.
MMUNITY
Infectious complications are common early after
CT. Immune reconstitution occurs gradually over G
B & M Time (generally 12-18 months). Immune recovery is
lower for allogeneic recipients, particularly those with
LA-mismatched transplants and T-cell depleted
rafts, and in survivors with graft-versus-host disease
GVHD). Bacterial, fungal, and viral infections may oc-
ur months or years after transplantation in those with
elayed reconstitution. Although infectious risk is high-
st in the ﬁrst 1-2 years after transplantation, risk of
nfection may continue long-term for some recipients
f allogeneic transplants. Patients who are immuno-
ompromised should be educated regarding their im-
une status and warning symptoms of infection and
hould be advised to seek early medical attention for
nfectious signs or symptoms. T-helper lymphocyte
CD4) counts and CD4/CD8 ratios are good mark-
rs of immune reconstitution. Some experts use abso-
ute CD4 levels (400/L) or CD4/CD8 ratio assess-
ents as surrogate markers of the completeness of
mmune reconstitution to guide duration of viral or
ther infection prophylaxis therapy. Some experts
rovide supplemental immune globulin for patients
ith severe infections and IgG levels less than 400
g/dL (4 g/L) and maintain levels until infection has
bated.
acteria
In patients with chronic GVHD (cGVHD), opso-
ization is impaired, and encapsulated bacteria (N.
eningitides, H. inﬂuenzae, and S. pneumonia) may cause
apidly progressive and life-threatening infection.
ungi
Aspergillus infection of the lungs or sinuses is
he most common late fungal infection. Candida and
ucor species are late pathogens occasionally.
iruses
Late-onset cytomegalovirus (CMV) infections
ave been reported more frequently in recent years
ith common prophylactic or preemptive use of an-
iviral drugs in the early post-HCT period. Late CMV
nfections are most commonly seen in patients treated
or early CMV infection or in those with chronic
VHD or late immune manipulation. Varicella zoster
irus (VZV) infection frequently occurs in the ﬁrst
ear after transplantation, especially in patients with
hronic GVHD. Recurrent herpes simplex virus
nfections are occasional complications of chronic
VHD.
ther Infectious Complications
Although Pneumocystis carinii (Pneumocystis jiroveci)
neumonia (PCP) generally occurs during the ﬁrst 6
onths after HCT, patients are at risk for as long
s immunosuppressive therapy is given for chronic
VHD. Autologous HCT recipients are also at risk of
139
Table 1. EBMT-CIBMTR-ASBMT Summary Recommendations for Screening and Prevention in Long-Term HCT Survivors
Tissues/Organs Late Complications Risk Factors Monitoring Tests and Preventive Measures
Immune system Infections Donor source
HLA disparity
T-cell depletion
Graft-versus-host disease (GVHD)
Venous access devices
Antibiotic prophylaxis targeting encapsulated organisms for duration of immunosuppressive therapy for
cGVHD. Some experts recommend antifungal prophylaxis for those receiving chronic corticosteroids
Administration of prophylactic antibiotics for oral procedures should follow American Heart Association
guidelines for endocarditis prophylaxis
PCP prophylaxis for initial 6 months for all HCT recipients, or duration of immunosuppressive therapy to
treat or prevent cGVHD
Some experts recommend continued CMV antigen or PCR testing for allogeneic recipients with chronic
immunosuppression or chronic GVHD. Some experts recommend prophylaxis for HSV in patients
receiving chronic immunosuppression for cGVHD
Immunizations per CDC or EBMT guidelines initiated at 1 y after HCT. Delayed initiation beyond 1 y may
be considered in situations where recipients are unlikely to respond
Oral Sicca syndrome
Caries
GVHD
Radiotherapy
Dental assessment at 6-12 mo; individualized follow-up schedule thereafter according to dental professional.
Subsequent dental/oral follow-up care should occur at least annually
Particular attention to intraoral malignancy evaluation in cGVHD patients and recipients of radiotherapy
Liver GVHD
Viral hepatitis
Iron overload
Cumulative transfusion exposure Liver function testing (LFT) every 3-6 months in first year, then individualized, but at least yearly
Monitor HbsAg and viral load by PCR for patients with known hepatitis B or C, with liver and infectious
disease specialist consultation
Liver biopsy to assess cirrhosis should be considered for those with chronic hepatitis C infection after 8-10 y
Serum ferritin at 1 y after transplant, with consideration of confirmatory liver biopsy for abnormal results
based upon magnitude of elevation and clinical context. Subsequent monitoring is suggested for patients
with elevated LFTs, continued RBC transfusions, or presence of hepatitis C infection
Muscle and
fascia
Myopathy
Myositis/fasciitis
Corticosteroids
GVHD
Frequent (monthly) clinical screening for corticosteroid myopathy
Physical therapy consultation for patients with prolonged corticosteroid exposure, fasciitis, or
sclerodermatous GVHD may minimize loss of function
Respiratory Interstitial pneumonitis
Bronchiolitis obliterans
Chronic obstructive
disease
Intensive conditioning regimen
Radiation exposure
Infectious agents
GVHD
Clinical assessment for all patients at 6 mo, 1 y, and annually thereafter
Avoidance of smoking tobacco should be recommended for all patients
Pulmonary function testing (PFT) and focused radiologic assessment for allogeneic recipients at 1 y for
signs or symptoms of compromise, or earlier as clinically indicated. Annual testing for those with deficits
or appropriate clinical circumstances. Some experts suggest screening PFT evaluation every 3-6 mo in
the first 2 y, particularly in patients with cGVHD
PFTs should be performed for autologous recipients with known pretransplant deficits or exposure to
radiation or other lung toxic agents
Radiographic evaluation as determined by diagnostic PFT testing or based on symptoms
Endocrine Hypothyroidism
Hypoadrenalism
Gonadal failure
Growth
Radiotherapy to head, neck,
mantle TBI
Prolonged corticosteroid usage
TBI
Intensive chemotherapy
Young age
Intensive prior chemoradiotherapy
CNS radiotherapy
Hypothyroidism
Gonadal insufficiency
TBI
Corticosteroids
Thyroid function testing yearly post transplant in all patients, or if relevant symptoms develop
Slow terminal tapering of corticosteroids for those with prolonged exposure
Consider stress doses of corticosteroids during acute illness for patents who had received chronic
corticosteroids
Annual clinical and endocrinologic gonadal assessment for postpubertal women
Clinical and endocrinologic gonadal assessment for prepubertal women within 1 y of transplant, with
further follow-up as determined by pediatric endocrinologist in the peripubertal period
Gonadal function in men, including FSH, LH, and testosterone, should be assessed as warranted by
symptoms (lack of libido, erectile dysfunction)
Monitor growth velocity in children annually, assessment of thyroid, and growth hormone function if growth
velocity is abnormal
J.D
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Table 1. Continued
Tissues/Organs Late Complications Risk Factors Monitoring Tests and Preventive Measures
Ocular Cataracts
Keratoconjunctivitis
sicca
Microvascular
retinopathy
TBI, corticosteroids
GVHD, TBI
Cyclosporine, radiotherapy
Routine clinical evaluation at 6 mo, 1 y, and yearly thereafter, with instruction regarding sicca and cataract
risk
Schirmer testing for those with cGVHD
Some experts recommend routine ocular exam (visual acuity; fundus exam) at 1 y for all patients,
subsequent frequency of screening individualized according to symptoms or predisposing factors
Prompt ophthalmologic examination in all patients with visual symptoms
Skeletal Osteopenia
Avascular necrosis
Corticosteroids
TBI
Inactivity
Gonadal insufficiency
Corticosteroids
TBI
Male gender
Dual photon densitometry at 1 y for adult women or any patient with prolonged corticosteroid or
calcineurin inhibitor exposure. Subsequent densitometry testing determined by defects or to assess
response to therapy
Exercise, calcium and vitamin D supplementation, and bisphosphonates are treatment options for
osteopenia and may help prevent loss of bone density. Clinicians should assess the role of gonadal and
thyroid function in patients with decreased bone density
Some experts recommend use of bisphosphonates as prophylaxis for patients at high risk due to chronic
corticosteroid usage
Screening for avascular necrosis is not recommended
Second cancers Solid tumors
Hematologic
malignancies
Posttransplant
lymphoproliferative
disorders
Chemotherapy
Radiotherapy
Immunodeficiency
Chronic GVHD
EBV infection
Risk awareness counseling annually
Screening clinical assessment annually
Routine self-examination of breasts and skin, as per health care maintenance section
Pap smear and mammogram annually as per health care maintenance section. Some experts recommend
screening mammography earlier than age 40 for women with radiation exposure
Avoidance of tobacco or excessive, unprotected UV exposure
Nervous system Leukoencephalopathy
Late infections
Calcineurin
neurotoxicity
Peripheral neuropathy
Cranial radiotherapy
Intrathecal chemotherapy
Fludarabine
GVHD
Chemotherapeutic exposure
Clinical evaluation for symptoms and signs of neurologic dysfunction at 1 y
Diagnostic testing (radiographs, nerve conduction, etc.) for those with symptoms or signs
Kidneys and
bladder
Nephropathy
Bladder dysfunction
TBI, platinum exposure
Adenovirus, CMV
Cyclophosphamide
Blood pressure assessment at every clinic visit, with aggressive hypertension management
Screening assessment of blood pressure, urine protein, BUN, and creatinine at 6 mo, 1 y, and annually if
abnormalities on earlier studies
Ultrasonography and/or renal biopsy as warranted to diagnose etiology of renal insufficiency
Vascular Coronary disease
Cerebrovascular
disease
Gonadal failure Routine clinical assessment of cardiovascular risk factors as per health maintenance
Clinical assessment for vascular complications at regularly scheduled follow-up visits
Testing for hypercoagulability for patients with significant thrombosis history
Quality of life
and
psychosocial
adjustment
Depression
Anxiety
Fatigue
Sexuality
Prior psychiatric morbidity
Gonadal failure
Clinical assessment throughout recovery period, at 6 mo, 1 y, and annually thereafter, with mental health
professional counseling recommended for those with recognized deficits
Encouragement of robust support networks
Query adults about sexual function at 6 mo and yearly
General health Recommended screening as per general population (see text)
Screening
and
Preventive
Practices
for
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1CP, particularly during the ﬁrst 6 months; risk may
e substantial if there has been prolonged corticoste-
oid exposure before transplantation or particularly
ntensive conditioning. Sinusitis is an occasional com-
able 2. EBMT-CIBMTR-ASBMT Abbreviated Summary
ecommendations for Screening and Prevention in Long-Term HCT
urvivors Organized by Time after Transplantation
Recommended Screening/Prevention 6 mo 1 y Annually
mmunity
Encapsulated organism prophylaxis 3 3 3
PCP prophylaxis 1 3 3
CMV testing 3 3
Immunizations 1 1
ral complications
Dental assessment 1 1 1
iver
Liver function testing 1 1 
Serum ferritin testing 1 
espiratory
Clinical pulmonary assessment 1 1 1
Smoking tobacco avoidance 1 1 1
Pulmonary function testing 2 
Chest radiography   
ndocrine
Thyroid function testing 1 
Growth velocity in children 1 1
Gonadal function assessment
(prepubertal men and women) 1 1 1
Gonadal function assessment
(postpubertal women) 1 1
cular
Ocular clinical symptom evaluation 1 1 1
Schirmer testing 3 3
Ocular fundus exam 1 
keletal
Bone density testing (women and
patients with prolonged
corticosteroid or calcineurin use) 1 
econd cancers
Second cancer vigilance counseling 1 1
Breast/skin/testes self-exam 1 1
Clinical screening for second
cancers 1 1
Pap smear/mammogram (over
age 40) 1 1
ervous system
Neurologic clinical evaluation 1 
idney
Blood pressure screening 1 1 1
Urine protein screening 1 1 
BUN/creatinine testing 1 1 1
ascular
Cardiovascular risk factor
assessment 1 1
sychosocial
Psychosocial/QOL clinical
assessment 1 1 1
Sexual function assessment 1 1 1
 recommended for all transplant patients.
 recommended for allogeneic patients only.
 recommended for any patient with ongoing cGVHD or immu-
nosuppression.
 reassessment recommended for abnormal testing in a previous
time period or for new signs/symptoms.lication, especially after allogeneic HCT, and is more c
42requent in patients with low immunoglobulin levels.
inus pathogens are rarely identiﬁed because invasive
iagnostic procedures are not frequently performed.
alcineurin antagonists induce mucosal hypertrophy
hat may add to sinus problems.
Recommendations:
Patients with chronic GVHD should have antibi-
otic prophylaxis targeting encapsulated organisms
given for as long as immunosuppressive therapy is
administered. Some experts recommend antifun-
gal prophylaxis in patients receiving chronic or
high-dose corticosteroids for cGVHD.
Administration of prophylactic antibiotics for oral
procedures should follow the American Heart As-
sociation guidelines [7] for endocarditis prophylaxis.
Some experts recommend that surveillance with
CMV antigen or PCR testing for allogeneic
HCT patients should be continued for the dura-
tion of chronic immunosuppression or chronic
GVHD. Similarly, some experts recommend pro-
phylaxis for HSV in patients receiving chronic
immunosuppression for cGVHD.
All HCT recipients should receive PCP prophy-
laxis for 6 months or as long as immunosuppres-
sive therapy is given for treatment/prevention of
chronic GVHD.
Immunization with inactivated vaccines should be
initiated at 1 year for all patients according to
either the CDC guidelines or EBMT guidelines
[8,9]. Physicians may consider delayed initiation
of immunization in situations where patients
have little ability to respond, such as active
steroid usage.
RAL COMPLICATIONS
Radiation therapy given as part of the condition-
ng regimen or as disease treatment before transplan-
ation causes reduced saliva production. This can be
hort-lived or persistent. Chronic GVHD can also
educe saliva production. Since saliva is a key host
efense against bacteria involved in dental caries, such
ndividuals are at high risk for dental caries. An assess-
ent for saliva production should be performed at the
nset of chronic GVHD and repeated during fol-
ow-up under the supervision of a dental professional
t intervals appropriate to the individual situation.
luoride treatments are often recommended. Artiﬁcial
aliva supplements may improve mastication of food
nd optimize nutrition.
Oral involvement with GVHD is frequent and can
e painful, interfere with oral intake, and be compli-
ated by infections. Chronic GVHD is a risk factor for
evelopment of intraoral malignancies. Corticosteroid
outh rinses or paste may improve symptoms ofhronic GVHD.
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Screening and Preventive Practices for Long-Term Survivors after HCT
BRecommendations:
Dental evaluation should be performed at 6-12
months after HCT to assess for caries and ade-
quacy of saliva production, educate for dental
hygiene, and consider ﬂuoride treatments. These
recommendations are suggested for all patients,
but especially for patients who have received ra-
diotherapy that involved the head and neck areas
and for those with a history of chronic GVHD.
Assessments in persons with long-standing chronic
GVHD or recipients of radiotherapy should in-
clude careful examination for head and neck ma-
lignancies, including oral malignancies at least
annually.
Schedules for subsequent routine dental follow-up
care should be individualized according to a den-
tist’s assessment or annually in accordance with
practices recommended for the general population.
IVER COMPLICATIONS
Identifying the etiology of liver dysfunction fol-
owing transplantation can be difﬁcult. Useful infor-
ation includes time of onset, type and trend of liver
est abnormalities, history of liver dysfunction before
r during transplantation, and presence of GVHD at
ther sites.
Chronic GVHD of the liver usually manifests as
holestasis with increased bilirubin and alkaline phos-
hatase. A liver biopsy should be considered to con-
rm clinical ﬁndings when isolated liver dysfunction
ccurs without other manifestations of GVHD. Ther-
py is with immunosuppressants. Ursodiol may be
ffective in conjunction with treatment of GVHD.
Patients with hepatitis B generally show mild to
oderate liver disease on long-term follow-up. Chronic
epatitis C is often asymptomatic with ﬂuctuating
ransaminase levels, but progression to cirrhosis and/or
alignancy may occur in as many as 25% of cases.
apering immunosuppressive therapy quickly and
onitoring of liver function tests and viral load are
ritical to allow early treatment. Patients with hepati-
is C virus (HCV) infection longer than 8-10 years
hould undergo liver biopsy to determine the degree
f chronic active hepatitis. The effectiveness of treat-
ent with ribavirin and/or interferon to prevent cir-
hosis is not known. Use of interferon after allogeneic
CT may be problematic because of potential exac-
rbation of GVHD. Patients with chronic hepatitis
ay beneﬁt from periodic consultation with a hepa-
ologist.
Most long-term survivors will have some degree
f iron overload as determined by serum ferritin
evels. However, since serum ferritin is an acute phase
eactant, it is primarily useful for screening for iron
verload, and many experts would recommend con- m
B & M Trmation with a liver biopsy depending upon the mag-
itude of elevation and the clinical context. Magnetic
esonance imaging is being investigated as a noninva-
ive means to assess liver iron content. The clinical
onsequences of iron overload in transplant recipients
ave not been extensively evaluated. Iron overload has
een associated with opportunistic infections and,
hen present in the setting of chronic viral hepatitis,
ay increase the risk of cirrhosis. Patients with iron
verload should be counseled to avoid iron supple-
ents and alcohol. Iron overload documented by liver
ron content greater than 7 mg/g dry weight should be
reated with phlebotomy and/or chelation therapy.
helation therapy may be associated with an increased
isk of fungal infections and should be used with
aution.
Recommendations:
Liver function tests (total bilirubin, alkaline phos-
phatase, and transaminases) should be performed
every 3-6 months for the ﬁrst year and then at
least yearly or on a more frequent schedule con-
sistent with individual patients’ situations.
For patients with known hepatitis B or C, moni-
toring of HbsAg and viral load by PCR and con-
sultation with liver and infection disease special-
ists is advised.
Liver biopsy should be considered in patients
with chronic hepatitis C infection to determine
the extent of cirrhosis. This is particularly crucial
in patients 8-10 years after HCT.
Serum ferritin should be measured 1 year post-
transplant, and if abnormal, conﬁrmatory liver
biopsy considered based upon the magnitude of
elevation and clinical context. Subsequent moni-
toring is suggested for the evaluation of elevated
LFTs with continued RBC transfusions or hepa-
titis C infection.
OMPLICATIONS OF MUSCLES AND FASCIA
Corticosteroid-induced muscle weakness is a con-
equence of selective atrophy of type II ﬁbers in prox-
mal muscles. It involves the legs more severely than
he arms and tends not to affect neck ﬂexor muscles.
yalgias frequently accompany the weakness. Weak-
ess may be improved by physical therapy and isomet-
ic exercise. A thorough physical therapy evaluation
nd an individually designed program of activities can
e helpful for maintaining and increasing strength.
henever possible, the corticosteroid dose should be
inimized. Alternate-day dosing reduces the risk of
yopathy. Myopathy may be slow to resolve follow-
ng discontinuation of corticosteroids.
Chronic GVHD may rarely produce polymyositis.
ymptoms include severe proximal muscle weakness,
yalgias, and arthralgias. Laboratory evidence in-
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1ludes elevated total creatine phosphokinase (CPK) or
ldolase and, sometimes, elevated antinuclear anti-
ody or rheumatoid factor titers. Muscle biopsy re-
eals necrotic muscle ﬁbers, interstitial inﬂammation,
nd IgG deposits on immune ﬂuorescent staining.
asciitis, a manifestation of chronic GVHD, and
clerodermatous GVHD limiting range of motion at
ajor joints may also occur. Therapy usually includes
mmunosuppressants.
Recommendations:
Clinical screening for corticosteroid-induced my-
opathy should take place monthly during therapy,
as onset may be insidious. Asking a patient to
stand from a sitting position may be revealing.
Patients with myalgias or arthralgias should be
evaluated for possible myositis.
Where prolonged corticosteroid exposure is an-
ticipated or when fasciitis or scleroderma devel-
ops, a physical therapy consultation can establish
baseline function and provide range-of-motion
and muscle-strengthening exercises to minimize
loss of function.
ESPIRATORY COMPLICATIONS
Pulmonary complications occur commonly in HCT
ecipients. Risk estimates are affected by the length
f follow-up and the type of routine assessments per-
ormed. Risk is generally higher with allogeneic trans-
lantation. Major risk factors include infections, the
xtent and type of chemotherapy exposure (precondi-
ioning and conditioning), radiation exposure, and
mmune-mediated lung injury. Mortality from late
ulmonary complications is substantial. The value of
creening with pulmonary function tests (PFTs) is not
ell deﬁned; however, it may be the most sensitive
arly indicator of bronchiolitis obliterans. Early diag-
osis may improve outcome since many conditions are
rreversible in the later stages.
Idiopathic pneumonia syndrome (IPS)/interstitial
neumonitis is common in the early posttransplant
eriod and can lead to late respiratory impairment.
tiologies include bacterial and viral infections, tox-
city from radiation or chemotherapy, and chronic
VHD. Immune compromise delays recovery from
nfection, allowing greater damage to the lung inter-
titium. Certain chemotherapeutic agents (BCNU,
leomycin, busulfan, methotrexate, and melphalan)
ause lung toxicity or enhance the damaging effects of
adiation. Fractionation of radiation and lung shield-
ng decrease radiation toxicity. Prophylaxis strategies
ocus on decreasing the risk of fungal and atypical
acterial lung infections such as PCP. Early identiﬁ-
ation of the cause of infections with improved viral
urveillance permits earlier treatment. Prompt recog-
ition of GVHD and institution of therapy may pre-
ent lung ﬁbrosis. a
44Bronchiolitis obliterans syndrome (BOS) (obstruc-
ive lung disease) occurs in 2-14% of allogeneic trans-
lant recipients. GVHD, infections, and aspiration in
hose with esophageal damage have been implicated in
evelopment of BOS, although etiologies are not well
eﬁned. BOS may develop in patients with no other
igns of chronic GVHD, and there may be minimal
adiographic changes. PFTs are the only effective
creening measure. Bronchodilator therapy may pro-
ide symptomatic relief but rarely improves obstruc-
ion. Corticosteroids and other immunosuppressive
herapy are effective in up to 50% of patients. Treat-
ent of infections may help prevent BOS. In patients
ith active GVHD, immune suppression with corti-
osteroids, cyclosporine, and/or other agents is appro-
riate.
Recurrent sinopulmonary infections are common
n transplant recipients, particularly those with long-
asting immune suppression for GVHD or those with
hronic tobacco smoke exposure. Smoking cessation is
ecommended for all patients. Appropriate vaccina-
ion is recommended, and in patients with ongoing
mmune deﬁciency, monitoring immune globulin lev-
ls is warranted, with targeted replacement as recom-
ended elsewhere in these guidelines.
Recommendations:
Routine clinical assessment (assessment of signs
and symptoms) is recommended for all patients at
6 months, 1 year, and yearly thereafter.
Smoking should be assessed (and discouraged)
during clinical assessments.
Pulmonary function testing (PFTs) and focused
radiologic assessment should be performed at 1
year after allogeneic transplantation for pa-
tients with signs or symptoms of lung compro-
mise or earlier as clinically indicated. Annual
testing is recommended thereafter for patients
with recognized defects or appropriate clinical
circumstances. Some experts suggest that more
frequent screening PFT evaluation (every 3-6
months in the ﬁrst 2 years) is warranted, partic-
ularly in patients with cGVHD.
For autologous HCT recipients, PFTs should be
performed for those with known deﬁcits pretrans-
plant or with exposure to radiation or other lung
toxic agents during or after transplantation.
Chest radiographic studies may be indicated based
on symptoms or abnormal PFTs, as well for reas-
sessment of previous radiographic abnormalities.
NDOCRINE COMPLICATIONS
Chemotherapy, radiation therapy, and HCT can
ll result in impairment of endocrine function. The
ost signiﬁcant endocrine complications are associ-ted with radiation exposure but are also related to
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Screening and Preventive Practices for Long-Term Survivors after HCT
Bome chemotherapeutic agents (busulfan), chronic
VHD, and prolonged corticosteroid exposure.
Subclinical, compensated hypothyroidism, with ele-
ated TSH and normal serum free T4 levels, occurs in
-15% of patients in the ﬁrst year after transplanta-
ion. The reported incidence of frank hypothyroidism
s variable depending upon risk factors in the popula-
ion studied. Single-dose ablative TBI is associated
ith a 50% incidence of overt hypothyroidism,
hereas fractionated TBI is associated with an inci-
ence of about 15%. The incidence reported after
usulfan and cyclophosphamide is 11%. Treatment
iven before transplantation likely also contributes to
he risk of thyroid abnormalities. The median time to
iagnosis of hypothyroidism is nearly 4 years. When
he TSH is elevated with normal T4 levels, assessment
hould be repeated in 2 months, or therapy should be
nitiated at the discretion of the treating physician.
atients diagnosed with hypothyroidism should re-
eive thyroid hormone replacement, with reassess-
ent about 6 weeks after initiation of therapy. Further
ndividual dose adjustment should be based on peri-
dic thyroid assessment, most often recommended
t 6-month intervals. Autoimmune thyroiditis is re-
orted; hyperthyroidism may also occur following ra-
iation. Radiation to the neck and total body irradia-
ion are associated with dose-related increases in risk
f thyroid malignancy, often with long latent periods.
Gonadal dysfunction is highly prevalent in HCT
ecipients, with rates as high as 92% for males and
9% for females. The degree of dysfunction is depen-
ent on age, gender, pretransplant therapy, and con-
itioning regimen. Although the risk of gonadal fail-
re is high in all individuals, women generally
xperience higher rates of failure than do men. Most
en have normal testosterone levels after transplan-
ation, although germ cell damage (infertility) is a
ear-universal ﬁnding in men exposed to high doses of
adiation or chemotherapy. Most reports suggest that
repubertal boys experience normal puberty and dem-
nstrate normal testosterone levels following HCT.
esting and consideration of hormone replacement
herapy for men is recommended based on symptoms.
ailure to progress through puberty in a timely fash-
on should prompt referral for a full endocrinology
valuation.
Women are at high risk of hypergonadotropic
ypogonadism after HCT. Hypogonadism is nearly
niversal after irradiation or busulfan. Risk is lower
ith cyclophosphamide alone. In general, ovarian en-
ocrine failure is irreversible in adult women, but
ounger women, particularly prepubescent girls, have
better opportunity for recovery of gonadal function.
ractionation of radiation reduces the risk compared
ith unfractionated radiation. Prepubertal girls should
e monitored closely for onset of puberty and, if puberty
s not experienced by age 12 to 13, be referred for full
B & M Tndocrinology evaluation and consideration of hormone
upplementation. Adult women should be evaluated by
gynecologist and will likely require hormone re-
lacement therapy to maintain libido, sexual function,
nd bone density. Libido is often decreased and only
artially corrected by HRT in women. Vaginal
VHD may result in strictures and synechiae. Sup-
lemental vaginal lubrication is of importance and
hould be addressed by the treating physician.
Infertility is almost inevitable in men and women
fter transplantation. Consideration should be given
o sperm or embryo preservation. Inadequate evidence
xists to support widespread use of ovarian cortical
issue strip banking as a means to restore ovarian
ormonal function after HCT outside of research
rotocols.
Transplant recipients have a low incidence of pri-
ary adrenal failure after HCT. Chronic therapy with
orticosteroids for GVHD will suppress the pituitary-
drenal axis, but function usually recovers gradually
nce exogenous corticosteroid exposure ends. Greater
ength and intensity of exposure is generally associated
ith longer persistence of adrenal suppression. Pa-
ients with prolonged exposure to corticosteroids after
CT should have adrenal axis testing when withdraw-
ng corticosteroids, particularly if symptoms of adre-
al insufﬁciency develop. Secondary hyperglycemia is
common consequence of corticosteroid usage.
Growth in children may be adversely affected by
CT, depending upon their pretransplant therapy
nd conditioning regimen. A large body of data sug-
ests that radiation is associated with growth defects
n children who receive HCT. Cranial radiation, in
articular, increases the risk of diminished growth in
hildren. Some reports suggest that chemotherapy
lone may cause growth deﬁciencies. Growth is a
omplicated process and may be adversely impacted
y many additional factors, including general illness,
utritional deﬁcits, hormonal deﬁciencies, long-term
orticosteroids, and GVHD. The risk of impaired
rowth is greatest in the youngest children. Children
hould be closely monitored for appropriate growth
elocity after HCT. A pediatric endocrinologist
hould evaluate children who do not achieve adequate
rowth, and assessment of growth hormone levels
hould be considered. Growth hormone deﬁciency
ollowing TBI has been demonstrated in some studies,
ut not in others. Since growth failure is likely to be
ultifactorial, consideration must be given to causes
ther than inadequate growth hormone. The beneﬁts
f growth hormone supplementation are unclear,
ince no randomized trial is reported. However, in
hildren with demonstrated deﬁciency, supplementa-
ion is commonly prescribed.
Recommendations:
Thyroid function tests (TSH, T3, and free T4)
should be performed yearly in all transplant re-
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1cipients and additionally if relevant symptoms
develop.
Yearly clinical and endocrinologic gonadal assess-
ment for women who were postpubertal at the
time of transplantation are recommended. Clini-
cal and endocrinologic gonadal assessment of pre-
pubertal girls should be initiated 6-12 months
after transplantation, with a further follow-up
schedule determined by a pediatric endocrinolo-
gist when the patient is in the peripubertal period,
and yearly thereafter.
Gonadal function in men, particularly FSH, LH,
and testosterone, should be assessed if symptoms
warrant (lack of libido or erectile dysfunction).
Patients withdrawing from prolonged corticoste-
roid usage should have slow terminal tapering of
corticosteroids; stress doses of corticosteroids
may be warranted during acute illness in patients
who have been on chronic corticosteroids in the
past.
Growth velocity should be monitored every year
in children, with assessment of thyroid function
and growth hormone if growth velocity is abnormal.
CULAR COMPLICATIONS
There are 3 main ocular late effects after HCT.
nterior segment ocular complications of keratocon-
unctivitis sicca syndrome and cataracts are well de-
cribed. Ischemic microvascular retinopathy is a pos-
erior segment complication that is being increasingly
ecognized.
Ocular sicca syndrome is usually part of a more
eneral sicca syndrome with xerostomia, vaginitis, and
ryness of the skin and is associated with chronic
VHD. Ocular manifestations include reduced tear
ow, keratoconjunctivitis sicca, sterile conjunctivitis,
orneal epithelial defects, and corneal ulceration. The
ncidence reaches 20% 15 years after HCT but is
igher (nearly 40%) in patients with chronic GVHD.
reatment includes aggressive management of chronic
VHD and continual use of topical lubricants. Top-
cal corticosteroids may improve symptoms but can
ause sight-threatening complications when inappro-
riately used in herpes simplex virus or bacterial ker-
titis. Topical retinoic acid or cyclosporine may also
e used. Lacrimal punctal occlusion may improve con-
unctival wetting. In general, contact lens usage is
iscouraged in patients with keratoconjunctivitis sicca
ecause of an increased risk of abrasion; however,
ome soft contact lenses may contribute to moisture
aintenance. Such an approach should occur only
ith the close supervision of an ophthalmologist.
Cataract formation is one of the most frequent late
omplications of TBI. After single-dose TBI, almost
ll patients develop cataracts within 3 to 4 years, and w
46ome need surgical repair. Fractionation of TBI re-
uces the incidence of cataract and delays onset. In
atients conditioned without TBI, the probability of
ataract formation at 10 years is 10%. Other risk
actors for cataract formation after HCT are older age
nd the use of corticosteroids. Cataracts are effectively
reated surgically. Surgery is indicated if vision is im-
aired and the impairment is interfering with daily
ife.
Ischemic microvascular retinopathy presents with
otton-wool spots and optic-disc edema. Retinopathy
s observed almost exclusively after allogeneic trans-
lantation, particularly in patients conditioned with
BI and receiving cyclosporine for GVHD prophy-
axis. In most cases, retinal lesions resolve with with-
rawal or reduction of immunosuppressive therapy,
ven in cases where visual acuity is decreased. Other
cular complications in the posterior segment include
emorrhage, bilateral optic disk edema, and infectious
etinitis (herpes viruses including CMV, toxoplasmo-
is, and fungi).
Recommendations:
Routine clinical evaluation of visual history and
symptoms, with attention to sicca syndrome, is
recommended at 6 months, 1 year, and yearly
thereafter.
Some experts recommend routine ocular exami-
nation with measurement of the visual acuity and
fundus examination at 1 year after transplant for
all individuals. Schirmer testing is recommended
in individuals with chronic GVHD. Subsequent
frequency of routine screening should be individ-
ualized according to recognized defects, ocular
symptoms, or the presence of chronic GVHD.
Patients should receive instruction regarding the
risk of cataracts and sicca syndrome.
Patients experiencing visual symptoms should un-
dergo ocular examination immediately.
KELETAL COMPLICATIONS
Osteopenia is a systemic condition characterized
y reduced bone mass and increased susceptibility to
one fracture. Osteoporosis is a more severe reduction
n bone mass with greater susceptibility to bone frac-
ure. The incidence and course of bone density ab-
ormalities following HCT have been studied in rel-
tively few large series. One year after transplantation
oth men and women may experience signiﬁcant loss
f bone density. The cumulative dose and duration of
orticosteroid therapy and the duration of cyclospor-
ne or tacrolimus therapy are associated with loss of
one mass. Preventive measures include regular phys-
cal activity, supplemental calcium and vitamin D, and
onsideration of estrogen replacement in deﬁcient
omen. Bisphosphonate therapy may reduce risk of
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Screening and Preventive Practices for Long-Term Survivors after HCT
Bracture in patients with established osteoporosis, al-
hough there are few clinical data supporting its use as
preventive measure.
Dual photon densitometry is currently the best
ool to assess the degree of osteopenia. Osteopenia
nd osteoporosis are differentiated by the degree of
eduction in bone mass and can be quantiﬁed by T and
scores by dual photon densitometry. Normal values
or bone density have not been well established in
hildren, although it is clear that the loss of bone
ensity and increased risk of fracture is a signiﬁcant
ssue in children after HCT. Treatment choices for
atients with osteopenia or osteoporosis include cal-
ium and vitamin D supplementation, judicious estro-
en replacement in women, exercise, reduction of
orticosteroids, and bisphosphonate therapy. Instruc-
ion regarding fall-prevention strategies is recom-
ended.
The incidence of avascular necrosis after HCT
AVN) is between 4% and over 10%. Pain is usually
he ﬁrst sign; however, standard radiographic evalua-
ion may not detect abnormalities until late in the
isease course. Early diagnosis is facilitated by mag-
etic resonance imaging. While the hip is the most
requent location (over 80% of the cases; bilateral
nvolvement in more than 60%), other joints can be
ffected, including the knees (10% of patients with
VN), wrists, and ankles. Symptomatic relief of pain
nd orthopedic measures to decrease pressure on the
oint can prove helpful, but most adult patients with
dvanced damage require surgical correction. While
he results of joint replacement by surgery are excel-
ent in the majority of the cases, long-term follow-up
f these prostheses is needed in young patients with a
ong life expectancy. Corticosteroids (both total dose
nd duration) are the strongest risk factor for devel-
pment of AVN. The other important risk factor is
BI (with the highest risk for a 10-Gy single dose or
12 Gy fractionated).
Recommended screening:
A screening dual photon densitometry should be
performed at 1 year after transplantation in adult
women or for any patient who has received pro-
longed treatment with corticosteroids or cal-
cineurin inhibitors. Repeat densitometry testing
should be performed in those with recognized
defects or to follow up the response to therapy.
Treatment options include vitamin D and cal-
cium supplementation, exercise, and bisphospho-
nates. Physicians should consider role of gonadal
and thyroid hormone function in patients with
declines in bone density.
Screening for avascular necrosis is not recom-
mended; however, clinicians should maintain a
high level of suspicion for patients with exposure
to irradiation or prolonged corticosteroids.
B & M TPractical measures such as physical exercise and
vitamin D and calcium supplementation may help
avoid a loss of bone density. Some experts recom-
mend the use of bisphosphonates for patients at
high risk by virtue of chronic corticosteroid usage.
ECONDARY MALIGNANCIES
Second malignancies after HCT are a devastating
ate complication. Patients receiving a allogeneic HCT
ave a 2- to 3-fold increased risk of developing solid
umors, compared with an age-, gender-, and region-
djusted population. Nearly all cancer types are de-
cribed after allogeneic and autologous transplant, in-
luding oral cancers, as mentioned above. Risk factors
nclude radiation therapy, length and severity of im-
unosuppression, and chronic GVHD. Risk increases
ith time after transplantation, particularly for radia-
ion-related malignancies. Recent analyses suggest
hat the risk of radiation-related solid tumors contin-
es to increase beyond 10 years posttransplantation.
he risk of secondary leukemia or myelodysplasia
MDS) after autologous HCT is also higher than
nticipated, with an overall incidence of about 4% at 7
ears after transplantation, with a median (range)
nset of 2.5 years (3 months to 7 years) post trans-
lantation. Risk appears to be increased for patients
eceiving prior alkylator therapy, prolonged administra-
ion of conventional chemotherapy, and higher doses
f pretransplant irradiation.
Posttransplant lymphoproliferative disorders (PTLD)
re a rare complication of allogeneic HCT associated
ith donor-recipient HLA disparity, T-cell depletion,
nd GVHD. The overall incidence is 1% at 10 years
fter HCT. Although these usually occur early (within
months of transplantation), PTLD is reported as
ate as 8 years after HCT. The majority of PTLD are
ssociated with Epstein-Barr virus infection. Quanti-
ative PCR detection of EBV can help establish the
iagnosis, and many patients respond to anti-CD20
onoclonal antibody therapy.
Exposure to radiation and the photosensitizing
ffects of many commonly used transplantation-
elated medications increase the risk of skin cancers
mong recipients. Patients should be encouraged to
educe UV skin exposure through the use of high-SPF
unscreens or skin coverage.
Recommendations:
All patients should be advised of the risks of
secondary malignancies annually and encouraged
to perform routinely recommended screening
self-examinations, such as breast and skin exami-
nation. Similarly, all patients should be encour-
aged to avoid high-risk behaviors as recom-
mended under the preventive health maintenance
section, including avoidance of tobacco or exces-
sive unprotected skin UV exposure.
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1Screening clinical assessment should be performed
yearly and should include symptom review for sec-
ondary malignancies. Clinical examination and
screening testing for secondary malignancies
should follow the recommendations outlined un-
der the health care maintenance section. Some
experts recommend initiation of screening mam-
mography earlier than age 40 for women with
radiation exposure.
ENTRAL AND PERIPHERAL NERVOUS
YSTEM COMPLICATIONS
Neurological complications after HCT may af-
ect the central and peripheral nervous systems and
re an important cause of morbidity. Though de-
cribed in all transplant recipients, reported compli-
ation rates appear to be lowest in autologous recipi-
nts and increased in allogeneic and especially
ecipients of transplants from donors other than
LA-identical siblings. Complications include late
NS infections in immunocompromised patients, ce-
ebrovascular complications such as subdural hema-
oma or stroke, calcineurin-induced CNS neurotoxic-
ty, leukoencephalopathy resulting from intrathecal
hemotherapy or cranial irradiation, and peripheral
europathies related to chemotherapy exposure or
uillain-Barré syndrome. Nearly 20% of patients
omplain of impaired memory, attention span, and
erbal ﬂuency. Pediatric patients may experience neu-
ocognitive deﬁcits or developmental delays following
xposure to radiation or chemotherapy. Subtle but
eaningful cognitive changes may be difﬁcult to de-
ect using formal testing techniques.
Recommendations:
All recipients of HCT should undergo clinical
evaluation for symptoms or signs of neurologic
dysfunction at 1 year after transplantation. Par-
ticular vigilance should be considered for those
who received allogeneic HCT, prolonged immu-
nosuppression with calcineurin inhibitors, TBI, cra-
nial irradiation, or intrathecal chemotherapy. Addi-
tional tests (radiographic testing, nerve conduction
studies, electromyography, neuropsychiatric testing,
etc.) may be warranted for those with symptoms or
signs.
ENAL COMPLICATIONS
Little is known about late renal dysfunction after
ransplantation, and the true incidence of end-stage
enal disease is not well deﬁned. Renal dysfunction
fter HCT can be caused by nephrotoxins used to
ontrol disease before transplantation, during condi-
ioning, and in the peritransplant period and may also be
elated to the underlying disease (eg, multiple myeloma),
48ype of transplant, recipient age, and previous renal func-
ion. Potential nephrotoxins include chemotherapy or
onditioning agents such as platinum compounds, car-
ustine, and ifosfamide; irradiation (including TBI),
ntifungal and antiviral agents (acyclovir, foscarnet, am-
hotericin B, and aminoglycoside antibiotics); and im-
unosuppressive therapy to prevent or treat GVHD
calcineurin inhibitors). Glomerulonephritis and ne-
hrotic syndrome are reported post HCT. Radiation
ephritis is frequent after TBI and can present more
han 6 months after HCT with renal impairment and
ypertension, with nephritic changes on urinalysis.
ggressive control of hypertension can substantially
mprove outcome.
Patients with substantial hemorrhagic cystitis in
he early posttransplant period experience a greater
isk of later bladder wall scarring and contraction.
Recommendations:
Blood pressure should be checked at every clinic
visit, and hypertension should be investigated and
managed aggressively (see detailed recommenda-
tions in the general health maintenance section
below).
Renal function should be evaluated at 6 and 12
months after transplantation for all patients and
yearly thereafter at a minimum for those with
early renal insufﬁciency. Screening should in-
clude assessment of urine protein, serum BUN,
and creatinine.
Ultrasonography should be used to exclude ob-
structive uropathy in patients with acute renal
insufﬁciency. Renal biopsy may delineate causes
of progressive or persistent renal insufﬁciency.
ASCULAR COMPLICATIONS
Vascular complications such as arterial cerebro-
ascular, cardiovascular, and peripheral vascular events,
s well as venous thrombosis and pulmonary embo-
ism, are reported at an unusually young age after
CT. However, since these complications are rare, it
s not yet clear whether they are higher after HCT
han in an age-matched general population. Screening
hould focus on regular assessment of established car-
iovascular risk factors as outlined under preventive
ealth and clinical assessment for unusual vascular
omplications.
Recommendations:
All patients should have routine assessment of
cardiovascular risk factors as outlined in the pre-
ventive health section, with recommendations for
lifestyle modiﬁcations as appropriate.
Clinical assessment for vascular complications
should be included at regularly scheduled fol-
low-up visits.
Patients experiencing signiﬁcant thrombosis should
undergo screening tests for known causes of hyper-
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Screening and Preventive Practices for Long-Term Survivors after HCT
Bcoagulability, including deﬁciency of protein C,
protein S, and antithrombin; factor V Leiden; the
prothrombin gene mutation; antiphospholipid
antibodies; and hyperhomocysteinemia.
SYCHOSOCIAL ADJUSTMENT
Depressive symptoms and psychological distress
re frequently observed in HCT survivors. Fatigue,
nger, insomnia, and problems with marital relation-
hips may also be seen. Pediatric patients may experi-
nce altered behavior patterns, changes in social hab-
ts, and changes in academic/school behavior. At the
ransition from acute convalescence to long-term
ollow-up, psychological distress may increase rather
han abate as the patient and his/her family must cope
ith changes in roles, employment situations, and
nancial difﬁculties. Sexual dysfunction occurs in a
igniﬁcant number of survivors and may be multifac-
orial in origin, from depression to gonadal hormonal
eﬁciency.
Spouses and other caregivers may also exhibit high
evels of depression and psychological distress. They
ften report loneliness and low levels of perceived
ocial support. Children may suffer from separation
rom 1 or both parents and the consequences of stress
nd upheaval in the family.
At a minimum, screening for depression is recom-
ended every 6-12 months after transplantation as
er the general health maintenance section below.
peciﬁc tools for screening for psychosocial difﬁcul-
ies after HCT are also available and could be used
ith a similar frequency to depression screening (Ap-
endix 1).
Recommendations:
A high level of vigilance for psychological symp-
toms should be maintained. Clinical assessment is
recommended throughout the recovery period, at
6 months, at 1 year, and annually thereafter, with
mental health professional counseling recom-
mended for those with recognized deﬁcits.
In adults, sexual function should be queried at a
minimum of 6 and 12 months after HCT (see
endocrine recommendations).
Inquiry as to the level of spousal/caregiver
psychological adjustment and family functioning
should be performed at regular intervals.
ENERAL SCREENING AND PREVENTIVE HEALTH
eneral Health Maintenance
In addition to transplant-speciﬁc diseases and
omplications mentioned above, HCT survivors re-
ain at risk of common diseases found in the general
opulation. Providers should remain mindful of these
isks in HCT survivors and should not neglect general
B & M Tealth care maintenance while focusing on transplant-
peciﬁc complications. In general, transplant survivors
hould be under the care of physicians comfortable
roviding care for general health and hematology-
ncology–speciﬁc issues. Summarized below are screen-
ng and lifestyle recommendations for the general
opulation. Further details on screening recommen-
ations can be found at http://www.ahrq.gov/clinic/
pipix.htm.
Recommended screening for all patients:
Hypertension: Blood pressure should be checked
at least every 2 years. In children, hypertension is
deﬁned as readings greater than the 95th percen-
tile for age, sex, and height. Treatment is indi-
cated for readings of greater than 140/90 mm Hg
in adults on 2 separate visits at least 1 week apart,
unless hypertension is mild and/or can be attrib-
uted to a temporary condition or medication (eg,
cyclosporine). Nonpharmacologic treatments may
also be tried for mild hypertension and include
moderate dietary sodium restriction, weight re-
duction in the obese, avoidance of excess alcohol
intake, and regular aerobic exercise.
Hypercholesterolemia: Cholesterol and HDL levels
should be checked every 5 years starting at age 35
for men and 45 for women. Screening should
start at age 20 for anyone who smokes, has dia-
betes, or has a family history of heart disease.
Note that fasting is not required for accurate
measurement of cholesterol and HDL but is re-
quired for LDL and triglycerides. Treatment
should be based on overall risk of heart disease
rather than absolute lipid levels (eg, greater than
a 1% chance of coronary heart disease per year).
Overall risk assessment should include the pres-
ence and severity of the following risk factors:
age, sex, diabetes, hypertension, family history (in
younger adults), and smoking. As a rough guideline,
total cholesterol levels 200 mg/dL (5.8 mmol/L)
or HDL levels 40 mg/dL (1.04 mmol/L) should
be followed up by a full fasting lipid panel.
Colorectal cancer: Screening should start at age
50 in the absence of a family history (ﬁrst-degree
relative diagnosed with colorectal cancer before age
60). The interval of testing depends on the type of
testing procedure and the prior screening results.
There are several screening tests, including annual
fecal occult blood testing (3 cards at home), sig-
moidoscopy every 5 years, double-contrast barium
enema every 5 years, and colonoscopy every 10
years. Virtual computerized tomography is a new
method, currently under investigation. No one
approach alone or in combination has proven
superior; however, a single digital rectal examina-
tion with occult blood testing is not sufﬁcient.
Diabetes: Screening is indicated for people with
high blood pressure or high cholesterol or in
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1those over age 45 every 3 years. Two common
tests for diabetes screening are the fasting plasma
glucose (FPG) or random plasma glucose and
hemoglobin A1c (HbA1c). A fasting plasma glu-
cose 126 mg/dL (6.9 mmol/L), a random
plasma glucose 140 mg/dL (7.7 mmol/L), or a
HbA1c 2 SD above the reference mean should
lead to further testing.
Depression: Asking 2 simple questions about mood
and anhedonia (“Over the past 2 weeks, have you
felt down, depressed, or hopeless?” and “Over the
past 2 weeks, have you felt little interest or plea-
sure in doing things?”) is probably as effective as
longer screening tools. The frequency of screen-
ing is not stated, but it is reasonable to screen
every 6-12 months posttransplantation or as clin-
ically indicated. Afﬁrmative answers to the ques-
tions above should trigger in-depth evaluation for
depression to determine the need for pharmaco-
logical or psychotherapeutic treatments.
Sexually transmitted diseases: All patients
should be counseled regarding the prevention
of sexually transmitted diseases. Chlamydia
screening is recommended for women under
age 25 who are sexually active. Screening and
appropriate treatment decrease the incidence of
pelvic inﬂammatory disease and pregnancy-re-
lated complications, although most women will
be infertile after myeloablative transplantation.
Male and female survivors should be reminded
that protection against sexually transmitted dis-
ease is important even when pregnancy is unlikely
or impossible.
Recommended screening for men:
Prostate cancer: There is no consensus about the
use of prostate-speciﬁc antigen or digital rectal
examination for prostate cancer screening.
Recommended screening for women:
Breast cancer: Screening with mammograms should
start at age 40 and occur every 1-2 years. Screen-
ing may be initiated earlier for young women
exposed to irradiation.
Cervical cancer: Screening with Papanicolaou
smears should be performed every 1-3 years in
people who are older than 21 or sexually active.
Osteoporosis: See the section on skeletal compli-
cations after HCT for more information.
Healthy lifestyle recommendations for all patients:
Alternative treatments, including herbal prepara-
tions, may have potent interactions with post-
transplantation medications. Patients should dis-
cuss all medications, including over-the-counter
medications, with their physician before usage to
avoid potentially deleterious effects.
Eat a healthy diet with a wide variety of foods.
Do not smoke or chew tobacco. a
50Be physically active 20-30 minutes most days of
the week.
Maintain a healthy weight.
Use alcohol in moderation, generally fewer than 2
drinks per day.
Avoid illicit substance abuse.
Take measures to prevent accidents and injury.
People should be counseled to wear seat belts
while in cars, helmets while riding bikes or mo-
torcycles, and appropriate safety equipment for
sporting activities.
Wear sunscreen protection at all times, and avoid
excessive sun exposure. This is particularly impor-
tant while on immunosuppressant medications.
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ung Self-Rating Depression Scale¶ 20 5-10 min Symptoms of depression
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